3,351 reports of this reaction
13.7% of all ESKETAMINE HYDROCHLORIDE reports
#1 most reported adverse reaction
DISSOCIATION is the #1 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 3,351 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to DISSOCIATION. This represents approximately 13.7% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience dissociation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISSOCIATION is a frequently reported adverse event for ESKETAMINE HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to dissociation, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
DISSOCIATION has been reported as an adverse event in 3,351 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISSOCIATION accounts for approximately 13.7% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dissociation while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.